Data obtained by Wu et al. (2019) both in vitro and in vivo suggest the potential presence of a dose-responsive window for some cancers that present certain genetic signatures as the ones involved in the cadherin–NF2–Hippo–YAP signaling axis, which is frequently mutated in cancer. This evidence concerns the gene NF2 and cancer.